Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · see citing works

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · see citing works

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · see citing works

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,542 · see citing works

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Gross, G., Waks, T., & Eshhar, Z. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10024 · Cited by 1,597 · see citing works

Therapeutic antibodies: successes, limitations and hopes for the future

Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382 · see citing works

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · see citing works

B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity

Sica, G., Choi, I.-H., Zhu, G., Tamada, K., Wang, S.-D., Tamura, H., Chapoval, A. I., Flies, D. B., Bajorath, J., & Chen, L. (2003) · Immunity · doi:10.1016/s1074-7613(03)00152-3 · Cited by 709 · see citing works

Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity

Wang, L.-C. S., Lo, A., Scholler, J., Sun, J., Majumdar, R. S., Kapoor, V., Antzis, M., Cotner, C. E., Johnson, L. A., Durham, A. C., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0027 · Cited by 653 · see citing works

Design and development of therapies using chimeric antigen receptor‐expressing T cells

Dotti, G., Gottschalk, S. M., Savoldo, B., & Brenner, M. K. (2013) · Immunological Reviews · doi:10.1111/imr.12131 · Cited by 510 · see citing works

Latest research and treatment of advanced-stage epithelial ovarian cancer

Coleman, R. L., Monk, B. J., Sood, A. K., & Herzog, T. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.5 · Cited by 489 · see citing works

Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia

Tran, E., Chinnasamy, D., Yu, Z., Morgan, R. A., Lee, C. R., Restifo, N. P., & Rosenberg, S. A. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130110 · Cited by 467 · see citing works

Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor

Zhao, Y., Moon, E. K., Carpenito, C., Paulos, C. M., Liu, X., Brennan, A. L., Chew, A., Carroll, R. G., Scholler, J., Levine, B. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2880 · Cited by 448 · see citing works

B7S1, a Novel B7 Family Member that Negatively Regulates T Cell Activation

Prasad, D. V. R., Richards, S., Muoi, X., & Dong, C. (2003) · Immunity · doi:10.1016/s1074-7613(03)00147-x · Cited by 431 · see citing works

B7x: A widely expressed B7 family member that inhibits T cell activation

Zang, X., Loke, P., Kim, J., MURPHY, K. M. M., Waitz, R., & Allison, J. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1434299100 · Cited by 401 · see citing works

Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex

King, M. A., Covassin, L., Brehm, M. A., Racki, W. J., Pearson, T., Leif, J., Laning, J. C., Fodor, W. L., Foreman, O., Burzenski, L. M., et al. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03933.x · Cited by 389 · see citing works

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo

Song, D.-G., Ye, Q., Poussin, M., Pritchard, G. H., Figini, M., & Powell, D. J. (2011) · Blood · doi:10.1182/blood-2011-03-344275 · Cited by 355 · see citing works

In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets

Beilhack, A., Schulz, S., Baker, J. B., Beilhack, G. F., Wieland, C. B., Herman, E. I., Baker, E. M., Cao, Y., Contag, C. H., & Negrin, R. S. (2005) · Blood · doi:10.1182/blood-2005-02-0509 · Cited by 352 · see citing works

Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo

Lanitis, E., Poussin, M., Klattenhoff, A. W., Song, D.-G., Sandaltzopoulos, R., June, C. H., & Powell, D. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0008 · Cited by 329 · see citing works

Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells

Frigault, M. J., Lee, J., Basil, M. C., Carpenito, C., Motohashi, S., Scholler, J., Kawalekar, O. U., Guedan, S., McGettigan, S. E., Posey, A. D., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0186 · Cited by 324 · see citing works

Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificity

Miotti, S., Canevari, S., Ménard, S., Mezzanzanica, D., Porro, G. A., Pupa, S. M., Regazzoni, M., Tagliabue, E., & COLNAGHI, M. I. (1987) · International Journal of Cancer · doi:10.1002/ijc.2910390306 · Cited by 315 · see citing works

Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma

Ritprajak, P., & Azuma, M. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2014.11.014 · Cited by 314 · see citing works

Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen-Specific Regulatory T Cells

Blat, D., Zigmond, E., Alteber, Z., Waks, T., & Eshhar, Z. (2014) · Molecular Therapy · doi:10.1038/mt.2014.41 · Cited by 246 · see citing works

Genomic Organization and Expression Analysis of B7-H4, an Immune Inhibitory Molecule of the B7 Family

Choi, I.-H., Zhu, G., Sica, G., Strome, S. E., Cheville, J. C., Lau, J. S., Zhu, Y., Flies, D. B., Tamada, K., & Chen, L. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.9.4650 · Cited by 244 · see citing works

The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation

Salceda, S., Tang, T., Kmet, M., Munteanu, A. I., Ghosh, M., Macina, R. A., Liu, W., Pilkington, G. R., & Papkoff, J. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.01.018 · Cited by 215 · see citing works

CAR T Cells for Solid Tumors

Kakarla, S., & Gottschalk, S. M. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000032 · Cited by 192 · see citing works

Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor

Lanitis, E., Poussin, M., Hagemann, I. S., Coukos, G., Sandaltzopoulos, R., Scholler, N., & Powell, D. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.256 · Cited by 187 · see citing works

A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- γc-/- double-mutant mice

van Rijn, R. S., Simonetti, E. R., Hagenbeek, A., Hogenes, M. C. H., de Weger, R. A., van Dijk, M. R., Weijer, K. C., Spits, H., Storm, G., van Bloois, L., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3241 · Cited by 186 · see citing works

In vivo imaging of graft-versus-host-disease in mice

Panoskaltsis‐Mortari, A., Price, A., Hermanson, J. R., Taras, E. P., Lees, C. J., Serody, J. S., & Blazar, B. R. (2004) · Blood · doi:10.1182/blood-2003-08-2827 · Cited by 150 · see citing works

B7-H4 overexpression in ovarian tumors

Tringler, B., Liu, W., Corral, L. G., Torkko, K. C., Enomoto, T., Davidson, S. A., Lucia, M. S., Heinz, D. E., Papkoff, J., & Shroyer, K. R. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.08.060 · Cited by 148 · see citing works

B7-H4 Expression in Human Melanoma: Its Association with Patients' Survival and Antitumor Immune Response

Quandt, D., Fiedler, E., Boettcher, D., Marsch, W. C., & Seliger, B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2268 · Cited by 135 · see citing works

Novel Recombinant Human B7-H4 Antibodies Overcome Tumoral Immune Escape to Potentiate T-Cell Antitumor Responses

Laniti, D. D., Lanitis, E., Zhao, A., Joshi, S., Cheng, Y., Sandaltzopoulos, R., Ra, H.-J., Danet-Desnoyers, G. A., Powell, D. J., & Scholler, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3457 · Cited by 118 · see citing works

The B7 family of immunoregulatory receptors: A comparative and evolutionary perspective

Hansen, J. D., Pasquier, L. D., Lefranc, M., Lopez, V., Benmansour, A., & Boudinot, P. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.10.007 · Cited by 113 · see citing works

The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus

Zhang, L., Wu, H., Lu, D., Li, G., Sun, C., Song, H., Li, J., Zhai, T., Huang, L., Hou, C., et al. (2013) · Oncogene · doi:10.1038/onc.2012.600 · Cited by 105 · see citing works

Potential Role of Decoy B7-H4 in the Pathogenesis of Rheumatoid Arthritis: A Mouse Model Informed by Clinical Data

Azuma, T., Zhu, G., Xu, H., Rietz, A. C., Drake, C. G., Matteson, E. L., & Chen, L. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000166 · Cited by 80 · see citing works

B7-H4–deficient mice display augmented neutrophil-mediated innate immunity

Zhu, G., Augustine, M. M., Azuma, T., Luo, L., Yao, S., Anand, S., Rietz, A. C., Huang, J., Xu, H., Flies, A. S., et al. (2008) · Blood · doi:10.1182/blood-2008-01-133223 · Cited by 80 · see citing works

Generation and Characterization of B7-H4/B7S1/B7x-Deficient Mice

Suh, W., Wang, S., Duncan, G. S., Miyazaki, Y., Cates, E. C., Walker, T. D., Gajewska, B., Deenick, E. K., Dawicki, W., Okada, H., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00755-06 · Cited by 76 · see citing works

Structure and Cancer Immunotherapy of the B7 Family Member B7x

Jeon, H., Vigdorovich, V. I., Garrett-Thomson, S. C., Janakiram, M., Ramagopal, U. A., Abadi, Y. M., Lee, J. S., Scandiuzzi, L., Ohaegbulam, K. C., Chinai, J. M., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.09.053 · Cited by 76 · see citing works

T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice

VanSeggelen, H., Hammill, J. A., Dvorkin‐Gheva, A., Tantalo, D. G. M., Kwiecień, J. M., Denisova, G. F., Rabinovich, B. A., Wan, Y., & Bramson, J. L. (2015) · Molecular Therapy · doi:10.1038/mt.2015.119 · Cited by 75 · see citing works

Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID β2mnull mice

Nervi, B., Rettig, M. P., Ritchey, J., Wang, H. L., Bauer, G., Walker, J. E., Bonyhadi, M. L., BERENSON, R. J., Prior, J. L., Piwnica-Worms, D. R., et al. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.06.007 · Cited by 74 · see citing works

NKG2D CAR T‐cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors

Spear, P., Barber, A. E., Rynda‐Apple, A., & Sentman, C. L. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.17 · Cited by 71 · see citing works

Host B7x Promotes Pulmonary Metastasis of Breast Cancer

Abadi, Y. M., Jeon, H., Ohaegbulam, K. C., Scandiuzzi, L., Ghosh, K., Hofmeyer, K. A., Lee, J. S., Ray, A., Gravekamp, C., & Zang, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202439 · Cited by 69 · see citing works

Tissue-specific expression of B7x protects from CD4 T cell–mediated autoimmunity

Wei, J., Loke, P., Zang, X., & Allison, J. P. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20100639 · Cited by 66 · see citing works

B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look

Smith, J. B., Stashwick, C., & Powell, D. J. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.03.553 · Cited by 65 · see citing works

B7-H4 Expression Promotes Tumorigenesis in Ovarian Cancer

Cheng, L., Jiang, J., Gao, R., Wei, S., Nan, F., Li, S., & Kong, B. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181ad0fa2 · Cited by 64 · see citing works

An Anti-B7-H4 Antibody–Drug Conjugate for the Treatment of Breast Cancer

Leong, S. R., Liang, W., Wu, Y., Crocker, L., Cheng, E., Sampath, D., Ohri, R. V., Raab, H. E., Hass, P. E., Pham, T., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/mp5007745 · Cited by 62 · see citing works

B7-H4 Expression by Nonhematopoietic Cells in the Tumor Microenvironment Promotes Antitumor Immunity

Rahbar, R., Lin, A., Ghazarian, M., Yau, H. L., Paramathas, S., Lang, P. A., Schildknecht, A., Elford, A. R., Garcia-Batres, C. R., Martin, B. G., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0113 · Cited by 47 · see citing works

Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer

Kreymborg, K., Haak, S., Murali, R., Wei, J., Waitz, R., Gasteiger, G., Savage, P. A., van den Brink, M. R. M., & Allison, J. P. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0100 · Cited by 39 · see citing works

B7x in the Periphery Abrogates Pancreas-Specific Damage Mediated by Self-reactive CD8 T Cells

Lee, J. S., Scandiuzzi, L., Ray, A., Wei, J., Hofmeyer, K. A., Abadi, Y. M., Loke, P., Lin, J., Yuan, J. D., SERREZE, D. V., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201241 · Cited by 34 · see citing works

Host B7-H4 Regulates Antitumor T Cell Responses through Inhibition of Myeloid-Derived Suppressor Cells in a 4T1 Tumor Transplantation Model

Leung, J., & Suh, W. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201242 · Cited by 26 · see citing works

Tissue-Expressed B7x Affects the Immune Response to and Outcome of Lethal Pulmonary Infection

Hofmeyer, K. A., Scandiuzzi, L., Ghosh, K., Pirofski, L., & Zang, X. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200701 · Cited by 24 · see citing works

B7-H4 Expression in Normal and Diseased Human Islet β Cells

Cheung, S. S. C., Ou, D., Metzger, D. L., Meloche, M. R., Ao, Z., Ng, S. S. W., Owen, D., & Warnock, G. L. (2013) · Pancreas · doi:10.1097/mpa.0b013e31829695d2 · Cited by 19 · see citing works

Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy

Lynn, R. C., & Powell, D. J. (2015) · Molecular Therapy · doi:10.1038/mt.2015.162 · Cited by 16 · see citing works

Isolation and Validation of Anti-B7-H4 scFvs from an Ovarian Cancer scFv Yeast-Display Library

Laniti, D. D., & Scholler, N. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2748-7_2 · Cited by 8 · see citing works

Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours

Flugel, C. L., Majzner, R. G., Krenciute, G., Dotti, G., Riddell, S. R., Wagner, D. L., & Abou‐El‐Enein, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00704-3 · Cited by 571 · see citing works

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape

Rodríguez-García, A., Palazón, A., Noguera-Ortega, E., Powell, D. J., & Guedan, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01109 · Cited by 317 · see citing works

The third group of the B7‐ CD 28 immune checkpoint family: HHLA 2, TMIGD 2, B7x, and B7‐H3

Janakiram, M., Shah, U. A., Liu, W., Zhao, A., Schoenberg, M., & Zang, X. (2017) · Immunological Reviews · doi:10.1111/imr.12521 · Cited by 225 · see citing works

Machine Learning Based Toxicity Prediction: From Chemical Structural Description to Transcriptome Analysis

Wu, Y., & Wang, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082358 · Cited by 193 · see citing works

B7-H4, a promising target for immunotherapy

Wang, J., & Wang, W. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.104008 · Cited by 101 · see citing works

High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation

MacGregor, H. L., Sayad, A., Elia, A., Wang, B. X., Katz, S. R., Shaw, P. A., Clarke, B. A., Crome, S. Q., Robert-Tissot, C., Bernardini, M. Q., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0816-5 · Cited by 78 · see citing works

A T-cell–engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer

Iizuka, A., Nonomura, C., Ashizawa, T., Kondou, R., Ohshima, K., Sugino, T., Mitsuya, K., Hayashi, N., Nakasu, Y., Maruyama, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3123 · Cited by 77 · see citing works

Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target

MacGregor, H. L., & Ohashi, P. S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2440 · Cited by 75 · see citing works

The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial

John, P., Yao, W., Liu, W., Du, M., Guan, F., & Zang, X. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.09.008 · Cited by 71 · see citing works

Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor

Minutolo, N. G., Sharma, P., Poussin, M., Shaw, L. C., Brown, D. P., Hollander, E. E., Smole, A., Rodríguez-García, A., Hui, J. Z., Zappala, F., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b11622 · Cited by 70 · see citing works

The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy

John, P., Pulanco, M. C., Galbo, P. M., Yao, W., Ohaegbulam, K. C., Zheng, D., & Zang, X. (2022) · Nature Communications · doi:10.1038/s41467-022-30143-8 · Cited by 43 · see citing works

CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar

Chen, K., Liu, M., Wang, J., & Fang, S. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9675 · Cited by 45 · see citing works

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

Toader, D., Fessler, S. P., Collins, S. D., Conlon, P. R., Bollu, R., Catcott, K. C., Chin, C., Dirksen, A., Du, B., Duvall, J. R., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0786 · Cited by 41 · see citing works

Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies

Najafi, S., & Mortezaee, K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122387 · Cited by 39 · see citing works

Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands

Kamali, A. N., Bautista, J. M., Eisenhut, M., & Hamedifar, H. (2023) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355231192043 · Cited by 38 · see citing works

Development of T-cell engagers selective for cells co-expressing two antigens

DiCara, D. M., Bhakta, S., Go, M. A. T., Ziai, J. M., Firestein, R., Forrest, B., Gu, C., Leong, S. R., Lee, G., Yu, S., et al. (2022) · mAbs · doi:10.1080/19420862.2022.2115213 · Cited by 24 · see citing works

Prognostic values of B7-H3, B7-H4, and HHLA2 expression in human pancreatic cancer tissues based on mIHC and spatial distribution analysis

Zhu, Y., Chen, J., Liu, Y., Zheng, X. W., Feng, J., Chen, X., Jiang, T., Li, Y., Zhang, J., & Chen, L. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153911 · Cited by 23 · see citing works

V-set domain containing T-cell activation inhibitor-1 (VTCN1): A potential target for the treatment of autoimmune diseases

Vaishnav, J., Khan, F., Yadav, M., PARMAR, N. R., Buch, H., Jadeja, S. D., Dwivedi, M., & Begum, R. (2022) · Immunobiology · doi:10.1016/j.imbio.2022.152274 · Cited by 22 · see citing works

CAR-Based Immunotherapy of Solid Tumours—A Survey of the Emerging Targets

Maher, J. F., & Davies, D. M. (2023) · Cancers · doi:10.3390/cancers15041171 · Cited by 22 · see citing works

A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity

Hammill, J. A., Kwiecień, J. M., Dvorkin‐Gheva, A., Lau, V. W. C., Baker, C. L., Wu, Y., Bezverbnaya, K., Aarts, C. W., Heslen, C. W., Denisova, G. F., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.04.001 · Cited by 19 · see citing works

CAR-T Cells Targeting Immune Checkpoint Pathway Players

Golubovskaya, V. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2704121 · Cited by 19 · see citing works

B7H4 Role in Solid Cancers: A Review of the Literature

Dawidowicz, M., Kot, A., Mielcarska, S., Psykała, K., Kula, A., Waniczek, D., & Świętochowska, E. (2024) · Cancers · doi:10.3390/cancers16142519 · Cited by 18 · see citing works

B7x—from bench to bedside

Kaur, G., & Janakiram, M. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000554 · Cited by 18 · see citing works

Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer

Li, Y., Chen, G.-L., Xiang, Z., Liu, Y., Li, X., Bi, J.-W., & Wang, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114648 · Cited by 18 · see citing works

Immune modulation by a cellular network of mesenchymal stem cells and breast cancer cell subsets: Implication for cancer therapy

Eltoukhy, H. S., Sinha, G., Moore, C. A., Sandiford, O. A., & Rameshwar, P. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.07.011 · Cited by 13 · see citing works

Immune Checkpoints of the B7 Family. Part 2. Representatives of the B7 Family B7-H3, B7-H4, B7-H5, B7-H6, B7-H7, and ILDR2 and Their Receptors

Chapoval, A. I., Chapoval, S. P., Shcherbakova, N. S., & Щербаков, Д. Н. (2019) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162019050091 · Cited by 12 · see citing works

Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer

Lv, C., Han, S., Wu, B., Liang, Z., Li, Y., Zhang, Y., Lang, Q., Zhong, C., Fu, L., Yu, Y. W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984172 · Cited by 12 · see citing works

B7H4 Expression Is More Frequent in MSS Status Colorectal Cancer and Is Negatively Associated with Tumour Infiltrating Lymphocytes

Dawidowicz, M., Kula, A., Mielcarska, S., Kiczmer, P., Skiba, H., Krygier, M., Chrabańska, M., Piecuch, J., Szrot, M., Robotycka, J., et al. (2023) · Cells · doi:10.3390/cells12060861 · Cited by 12 · see citing works

Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model

Chand, D., Dhawan, D., Sankin, A. I., Ren, X., Lin, J., Schoenberg, M., Knapp, D. W., & Zang, X. (2019) · Bladder Cancer · doi:10.3233/blc-180204 · Cited by 12 · see citing works

The role of B7-H4 in ovarian cancer immunotherapy: current status, challenges, and perspectives

Zhou, L., Duan, Y., Fu, K., Zhang, M., Li, K., & Yin, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1426050 · Cited by 11 · see citing works

SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy

Benard, E., Casey, N. P., Inderberg, E. M., & Wälchli, S. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12917 · Cited by 12 · see citing works

B7-H4 is Inversely Correlated With T-Cell Infiltration in Clear Cell but Not Serous or Endometrioid Ovarian Cancer

Pagnotti, G. M., Atkinson, R. M., Romeiser, J. L., Akalin, A., Korman, M., & Shroyer, K. R. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000608 · Cited by 11 · see citing works

Prospects and challenges of CAR-T in the treatment of ovarian cancer

Chen, B., & Liu, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112112 · Cited by 10 · see citing works

The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1

Sankin, A. I., Narasimhulu, D. M., John, P., Gartrell, B. A., Schoenberg, M., & Zang, X. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.04.007 · Cited by 10 · see citing works

Innovative approaches to CAR-T cell therapy: the role of lipid metabolism pathways

Guo, M., Zhang, Y., Yuan, X. H., & Wang, X. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06718-6 · Cited by 9 · see citing works

Role of B7 family members in glioma: Promising new targets for tumor immunotherapy

Wang, Y., Li, M., Wang, G., & Wu, H. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1091383 · Cited by 8 · see citing works

Analysis of B7-H4 expression in metastatic pleural adenocarcinoma and therapeutic potential of its antagonists

Chen, C., Qu, Q., Xie, F., Zhu, W., Zhu, Y., & Huang, J. (2017) · BMC Cancer · doi:10.1186/s12885-017-3615-8 · Cited by 8 · see citing works

Depleting Tumor Cells Expressing Immune Checkpoint Ligands—A New Approach to Combat Cancer

Marcucci, F., & Rumio, C. (2021) · Cells · doi:10.3390/cells10040872 · Cited by 8 · see citing works

B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy

Chen, X., Li, J., Chen, Y., Que, Z., Du, J., & Zhang, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315005 · Cited by 6 · see citing works

Chimeric antigen receptor T cell immunotherapy for gynecological malignancies

Gao, Y., He, J. N., Wang, J., Xu, H., & Ma, L. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104680 · Cited by 5 · see citing works

Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities

Kang, N., Xue, H., Wong, N. K. Y., Lin, Y., Classen, A., Wu, R., Oo, H. Z., Dong, X., Trinh, A. M., Lin, D., et al. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0958 · Cited by 4 · see citing works

A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies

Abayasiriwardana, K. S., Wu, L., Laklai, H., Nocula‐Ługowska, M., Tchistiakova, L., Narula, J., Jackson-Fisher, A. J., Golas, J., Lam, M., Grinstein, V., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0379 · Cited by 4 · see citing works

Altered Levels of Negative Costimulatory Molecule V-Set Domain-Containing T-Cell Activation Inhibitor-1 (VTCN1) and Metalloprotease Nardilysin (NRD1) are Associated with Generalized Active Vitiligo

Vaishnav, J., Jadeja, S. D., Singh, M., Khan, F., Yadav, M., & Begum, R. (2022) · Immunological Investigations · doi:10.1080/08820139.2022.2097091 · Cited by 4 · see citing works

B7-H4: a multifaceted immune checkpoint and oncoprotein in cancer biology and immunotherapy

Zhang, C., Miao, Z., Cao, J., Wang, X., & Shi, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1837397 · Cited by 3 · see citing works

Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma

Wen, H., Lou, X., Qu, Z., Qin, C., Jiang, H., Yang, Y., Kang, L., Geng, X., Yu, L., & Huang, Y. (2022) · Discover Oncology · doi:10.1007/s12672-022-00588-w · Cited by 3 · see citing works

Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumor antigens original from T‐ALL‐iPSC in vivo

Li, W., Zhou, M., Wang, L., Huang, L., Chen, X., Sun, X., & Liu, T. (2023) · Cancer Innovation · doi:10.1002/cai2.95 · Cited by 3 · see citing works

Next generation immune checkpoints

Perez, N. M., Moziak, K., & Martin, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.90009-2 · Cited by 1 · see citing works

Pathology associated with human CAR T cell administration in NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice: A retrospective analysis

Mammone, R. M., Willis, E., Ruivo, P., Finesso, G., Cox, A., Assenmacher, C., Radaelli, E., Piersigilli, A., & Miranda, I. C. (2026) · Veterinary Pathology-Supplement · doi:10.1177/03009858251409216 · Cited by 1 · see citing works

RCAS1 and B7H4 antigens immunoreactivity in squamous cell carcinoma of palatine tonsils and cancer microenvironment

Dutsch-Wicherek, M. M., Lazar, A., Tomaszewska, R., Kliś, K. M., Dziobek, K., & Wicherek, Ł. (2018) · Medical Research Journal · doi:10.5603/mrj.a2018.0022 · Cited by 1 · see citing works

Prostate cancer surface targets for CAR T cell therapy or metastatic prostate cancer in the CAR T cell era: My kingdom for the target!

Kulemzin, S. V., Gorchakov, A. A., & Taranin, A. V. (2019) · Cellular Therapy and Transplantation · doi:10.18620/ctt-1866-8836-2019-8-4-19-28 · Cited by 1 · see citing works

Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphomaPreprint

Wen, H., Lou, X., Qu, Z., Qin, C., Jiang, H., Yang, Y., Kang, L., Geng, X., Yu, L., & Huang, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1916684/v2

Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphomaPreprint

Wen, H., Lou, X., Qu, Z., Qin, C., Jiang, H., Yang, Y., Kang, L., Geng, X., Yu, L., & Huang, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1916684/v1

Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

Toader, D., Fessler, S. P., Collins, S. D., Conlon, P. R., Bollu, R., Catcott, K. C., Chin, C., Dirksen, A., Du, B., Duvall, J. R., et al. (2023) · doi:10.1158/1535-7163.c.6821443

Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

Toader, D., Fessler, S. P., Collins, S. D., Conlon, P. R., Bollu, R., Catcott, K. C., Chin, C., Dirksen, A., Du, B., Duvall, J. R., et al. (2023) · doi:10.1158/1535-7163.c.6821443.v1

Application and progress of CAR therapy on malignances: from CAR-T to CAR-NK

Zhang, Q. (2024) · MedScien · doi:10.61173/ve5wzw54

WITHDRAWN: Next generation immune checkpoints

Perez, N. M., Moziak, K., & Martin, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00009-6

Developing logic-gated CAR T cells for saferT-cell lymphoma therapy

Bourbon, E. (2025) · theses.fr (ABES) · doi:10.70675/11e2363dzeb1fz46bcza38dz6f6c7aa5545d

B7-H4 in Cancer Immune Evasion and Immunotherapy

Xiao, R., Yu, J., Yan, Y., Kryczek, I., & Zou, W. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2442

514. Targeting the Negative Immune Regulatory Molecule B7-H4 on Both Tumor and Normal Tissue With Anti-B7-H4 CAR T Cells

Smith, J. B., Lanitis, E., Laniti, D. D., Poussin, M., McLane, M. P., Scholler, N., & Powell, D. J. (2015) · Molecular Therapy · doi:10.1016/s1525-0016(16)34123-5 · Cited by 1 · see citing works

Treating cancer with engineered T cell therapies: Murine and canine models of safety and efficacy

Smith, J. B. (2016) · ScholarlyCommons (University of Pennsylvania)

B4M3 CAR-T cell enhance antitumor activity and non-tumor toxicity in ovarian cancer

Ji, F., Yu, J. J., Zhu, Y., Lin, H., Gao, K., Rao, M., Shan, Y., Liu, S., Ding, B., & Shen, Y. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114919 · Cited by 4 · see citing works

Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 Via Chimeric Antigen Receptor T CellsPreprint

Du, H., Hirabayashi, K., Ahn, S., Kren, N. P., Montgomery, S. A., Wang, X., Tiruthani, K., Mirlekar, R., Michaud, D. E., Greene, K. G., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3280238 · Cited by 1 · see citing works

B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity

Wu, M.-R., Zhang, T., DeMars, L. R., & Sentman, C. L. (2015) · Gene Therapy · doi:10.1038/gt.2015.29 · Cited by 64 · see citing works